NMN and NR for Adults 65+: School, Daily Activity, and Physical Performance Considerations

Why NAD+ Decline Matters Specifically After Age 65

After 65, the metabolic consequences of NAD+ depletion become clinically visible. Muscle mass falls at 1 to 2 percent per year after age 60, mitochondrial function in skeletal muscle deteriorates, and DNA repair capacity drops. All three processes depend on adequate NAD+ availability. NMN and NR are the two oral precursors with the most human trial data, and both are absorbed and converted to NAD+ within hours of ingestion.

The Biology of NAD+ Loss in Aging Tissue

NAD+ is a coenzyme used by sirtuins (SIRT1 through SIRT7), PARPs, and CD38. With age, CD38 activity rises sharply, consuming NAD+ faster than biosynthesis can replace it. A 2020 study published in Cell Metabolism showed that CD38 expression in adipose macrophages was the dominant driver of tissue NAD+ decline in aged mice, rather than reduced synthesis alone [1]. This finding shifted mechanistic understanding and partly explains why precursor supplementation alone may not fully restore NAD+ in the oldest tissues.

What Serum and Tissue NAD+ Levels Look Like at 65+

Measuring NAD+ accurately in humans is technically difficult. Whole-blood NAD+ is the most commonly used proxy. In a placebo-controlled trial by Trammell et al. In Nature Communications, single-dose NR 1,000 mg raised whole-blood NAD+ by 2.7-fold above baseline in healthy adults within 9 hours [2]. Whether that elevation translates to muscle or brain tissue in adults over 65 is less clear. A 2022 study in npj Aging found that skeletal muscle NAD+ did not rise significantly in older men after 12 weeks of NMN 400 mg/day despite clear increases in blood NAD+ metabolites [3].

Dosing Frameworks for Adults 65 and Older

No geriatric-specific dosing guideline exists. Current recommendations are extrapolated from adult trials, adjusted for lower renal clearance and the higher prevalence of polypharmacy in this age group.

NMN Dose Ranges Studied in Humans

The lowest effective dose studied was 250 mg/day. Yoshino et al. (2021, N=25 postmenopausal women with prediabetes or obesity, mean age 57, 10 weeks) showed that NMN 250 mg/day improved skeletal muscle insulin sensitivity and upregulated genes linked to muscle remodeling compared with placebo [4]. The dose was well tolerated with no serious adverse events.

Higher doses have been tested. A Japanese RCT by Igarashi et al. (2022, N=36 healthy older men aged 65 to 80, 12 weeks) used NMN 250 mg/day versus placebo and found modest improvements in muscle strength and gait speed in the NMN group, though the between-group difference for gait speed did not reach statistical significance (P = 0.08) [5]. Doses up to 1,200 mg/day in a Phase 1 safety study at Washington University were tolerated without dose-limiting toxicity, though the subjects were younger adults [6].

NR Dose Ranges Studied in Humans

NR at 1,000 mg/day (500 mg twice daily) was used in the CALERIE-NR pilot (N=12, adults aged 55 to 79, 21 days), which showed a 40 to 50 percent increase in peripheral blood mononuclear cell NAD+ without significant adverse effects [7]. A larger trial by Dollerup et al. In Nature Communications (N=40, obese men, 12 weeks, NR 2,000 mg/day) found no improvements in insulin sensitivity despite NAD+ elevation, suggesting that blood NAD+ increases do not automatically translate to metabolic benefit [8].

Practical Starting Point for Adults Over 65

Given the available data, a reasonable starting framework for adults 65 and older is:

• NMN: Begin at 250 mg once daily with breakfast. After 4 to 6 weeks, titrate to 500 mg/day if tolerated. Doses above 500 mg/day in this age group lack controlled safety data beyond 12 weeks.
• NR: Begin at 250 to 300 mg once daily. A common commercial dose is 300 mg. Titrate to 500 mg twice daily only if the lower dose produces no GI side effects after 3 to 4 weeks.
• Timing: Morning dosing with food. NAD+ biosynthesis peaks in the early active phase of the circadian cycle, and food reduces nausea.
• Monitoring: Fasting glucose at baseline and 8 to 12 weeks (both compounds may affect insulin signaling). Review concurrent medications, especially metformin.

Physical Activity and Exercise Timing Considerations

For older adults enrolled in structured activity programs, whether that is a community fitness class, a cardiac rehabilitation program, or a supervised strength-training routine, the interaction between NAD+ precursor timing and exercise is worth understanding.

Does NMN or NR Improve Exercise Capacity in Older Adults?

Modest improvements have been reported. The Igarashi et al. Trial mentioned above found that NMN 250 mg/day over 12 weeks improved knee extensor strength by approximately 9 percent in the treatment group versus 3 percent in the placebo group [5]. That 6-percentage-point difference is clinically meaningful in a population where sarcopenia risk is high.

A 2023 randomized trial by Yi et al. (N=80, adults aged 40 to 65, 60 days, NMN 600 mg/day or 1,200 mg/day) showed dose-dependent improvements in aerobic capacity as measured by VO2max and walking distance on a 6-minute walk test [9]. The 1,200 mg/day group showed a 6.1 percent VO2max increase versus 1.8 percent in placebo (P<0.05). These subjects were not strictly geriatric, but the findings are informative for the 65 to 70 transition age.

Timing NMN or NR Around Exercise Sessions

No published pharmacokinetic trial has specifically examined pre-exercise versus post-exercise dosing of NMN or NR in older adults. Based on available PK data showing peak plasma NMN at approximately 2 to 3 hours post-ingestion and peak NAD+ elevation at 5 to 9 hours [2], dosing 2 to 3 hours before planned physical activity may align peak availability with the exercise window. This is a mechanistic inference, not a trial-validated recommendation.

Resistance Training Synergies

Resistance training independently upregulates NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway. A 2020 study in FASEB Journal showed NAMPT expression increased significantly in skeletal muscle after 12 weeks of resistance training in older adults (mean age 66) [10]. Combining resistance training with NMN or NR supplementation may therefore produce additive effects on muscle NAD+ levels, though a head-to-head trial testing this combination in a purely geriatric cohort has not yet been published.

Cognitive Engagement, Lifelong Learning, and NAD+ in the Aging Brain

Adults 65 and older who remain engaged in educational activities, language learning, instrument playing, or formal coursework (sometimes called "senior school" programs) are a meaningful subpopulation asking about NAD+ precursors. The question is whether NMN or NR supports cognitive function enough to be relevant for learning performance.

Current Human Evidence for Cognitive Outcomes

Human trial data are limited. No RCT has yet reported cognitive learning outcomes as a primary endpoint for NMN or NR in adults specifically over 65. The most relevant human data come from a 2019 study by Dahl et al. In Current Developments in Nutrition (N=10, adults aged 55 to 79, NR 1,000 mg/day for 21 days) which measured Montreal Cognitive Assessment (MoCA) scores and found no statistically significant change over the short study period [7]. The study was underpowered and too short to draw firm conclusions.

Mechanistic Data from Preclinical Models

Mouse models are more encouraging. A 2013 study in Cell by Gomes et al. Showed that raising NAD+ levels in aged mice (18 to 22 months) via NMN injection restored mitochondrial function to levels comparable to 6-month-old mice within one week [11]. Cognitive behavioral tests in similar aged-mouse studies showed improvements in spatial memory after NMN treatment, though translating rodent cognition data to human learning outcomes requires caution.

Practical Considerations for Cognitively Active Older Adults

For adults participating in structured educational programs, the most evidence-backed strategy remains aerobic exercise combined with sleep hygiene, as both independently support hippocampal neurogenesis. NMN or NR may complement that foundation. No clinical provider should represent these supplements as cognitive enhancers in the absence of RCT data in the 65+ human population.

Safety Profile and Drug Interactions at Age 65+

The safety record so far is reassuring but limited to trials of 12 weeks or shorter. Longer-term data in geriatric populations are absent.

Adverse Effects Reported in Trials

Across published trials, the most common adverse effects were mild GI complaints: nausea, loose stools, and abdominal discomfort. These were dose-dependent and more frequent at doses above 1,000 mg/day. A systematic review by Mehmel et al. Published in Nutrients covering 11 human NMN and NR trials found no serious adverse events reported across studies with a combined N of approximately 350 participants [12]. The review authors noted that none of the included trials exceeded 12 weeks, limiting conclusions about long-term safety.

Drug Interactions Relevant to Geriatric Patients

Polypharmacy is common after 65. The clinically relevant interactions include:

Metformin: Both NMN and metformin activate AMPK pathways. Concurrent use may produce additive glucose-lowering effects. Monitor fasting glucose if a patient on metformin starts NMN or NR at doses above 500 mg/day.

PARP inhibitors (olaparib, rucaparib, niraparib): PARPs are NAD+-consuming enzymes. Theoretically, raising NAD+ with NMN or NR could reduce the efficacy of PARP inhibitors used in oncology. No clinical data exist confirming this interaction, but the mechanistic concern is enough to recommend caution and oncology consultation before starting NAD+ precursors in patients on PARP inhibitor therapy.

Warfarin: No known pharmacokinetic interaction. Nicotinamide at high doses has shown mild antiplatelet properties in some in vitro studies, but this has not been replicated for NMN or NR at clinical doses. INR monitoring per standard practice.

Statins: Some statins modestly reduce CoQ10 and mitochondrial function; NMN or NR may theoretically offset some mitochondrial effects of statins, though no clinical trial has evaluated this combination.

Renal and Hepatic Considerations

Adults over 65 frequently have reduced glomerular filtration rates. NMN is primarily metabolized to NAD+ intracellularly and its metabolites are renally excreted. In a Phase 1 trial, Irie et al. (2020, N=10, healthy Japanese men, single doses of NMN 100 to 500 mg) found no adverse changes in renal or hepatic function markers at any dose [6]. Creatinine, AST, and ALT remained within normal ranges. This study used only single doses, and repeated dosing in patients with CKD Stage 3 or higher has not been formally studied.

Structured Activity Programs: Institutional and Community Settings

Many adults 65 and older participate in organized programs: senior fitness classes at YMCAs, hospital-based cardiac rehabilitation, community colleges with lifelong learner programs, or adult day health centers. How should NMN or NR supplementation be integrated into those settings?

Communicating With Program Coordinators and Instructors

Supplement use is common in this age group. A 2020 CDC survey found that over 70 percent of adults 65 and older reported taking at least one dietary supplement [13]. Program coordinators at fitness centers and learning institutions are not medical providers and cannot give dosing advice. Participants should be encouraged to disclose supplement use to the supervising clinician who manages their medical care, not to fitness instructors.

Screening Before Starting in an Activity Program

Before a geriatric adult begins both a new structured exercise program and NMN or NR supplementation simultaneously, a brief pre-activity screening using the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) is appropriate. The American Heart Association notes that older adults with cardiovascular disease should obtain physician clearance before starting vigorous exercise programs [14]. Adding a new supplement at the same time complicates attribution of any adverse event, so staggering the start by 2 to 4 weeks is reasonable.

Fall Risk and Lower-Extremity Strength

Falls are the leading cause of injury-related death in adults 65 and older in the United States. Sarcopenia and reduced lower-extremity muscle power are primary contributors. The modest grip strength and knee extensor improvements seen in the Igarashi et al. NMN trial [5] suggest that NMN, as an adjunct to resistance training, may contribute to fall-risk reduction programs, though no trial has used falls as a primary endpoint.

What the Current Evidence Does Not Support

Honest framing matters in this population.

NMN and NR are not approved treatments for any disease. They are not indicated for dementia, Alzheimer's disease, Parkinson's disease, or osteoporosis. The FDA has not approved any NMN or NR product for therapeutic use, and both remain regulated as dietary supplements under the Dietary Supplement Health and Education Act of 1994 [15]. Claims that these compounds reverse aging, restore youthful cognition, or prevent age-related disease are not supported by current clinical trial evidence in humans.

A direct quotation from the Washington University research group summarizes this well. Dr. Samuel Klein, co-investigator on the Yoshino 2021 trial, stated in an accompanying press release: "Although this study demonstrates that NMN supplementation can increase NAD levels and have beneficial metabolic effects, we still need more clinical trials to determine its safety and efficacy in different populations." [4]

The National Institute on Aging has similarly noted in its research priorities that: "The translation of preclinical NAD+ research to human aging interventions requires carefully designed trials with aging-specific endpoints, including functional independence, fall rates, and cognitive decline, none of which have yet been fully addressed." [16]

Monitoring and Follow-Up for Geriatric Patients on NMN or NR

If a provider decides supplementation is appropriate for a patient over 65, a minimum monitoring plan should include:

• Baseline and 8-to-12-week fasting glucose and HbA1c (particularly if the patient has prediabetes or is on metformin)
• Baseline BMP to document renal function; repeat at 12 weeks for patients with CKD Stage 2 or higher
• Review of all concurrent medications at each visit for the interactions listed above
• Functional assessment at baseline and 12 weeks: grip strength using a hand dynamometer, 30-second chair stand test, and gait speed over 4 meters

Grip strength below 27 kg in men and 16 kg in women meets the European Working Group on Sarcopenia in Older People (EWGSOP2) diagnostic threshold for sarcopenia [17]. Documenting grip strength at baseline provides an objective marker to assess whether any functional benefit is occurring over time.